36 results about "Cotransporter" patented technology

The present disclosure relates to the endothelin receptor antagonist (ERA) zibotentan in combination with the sodium-dependent glucose cotransporter 2 (SGLT-2) inhibitor dapagliflozin for use in the treatment of certain endothelin related diseases.

Disclosed are methods of using an aldosterone synthase inhibitor of formula (1) for treating, reducing the risk of, or delaying the progression of heart failure related disorders. The invention further relates to methods of using Compound 1 in combination with sodium-glucose cotransporter-2 (SGLT2) inhibitors.

The invention discloses a pugionium cornutum cation-Cl-co-transporter protein coding gene PcCCC1 and application thereof. The nucleotide sequence of the cation-Cl-co-transporter protein coding gene PcCCC1 is as shown in SEQ ID No.1, the amino acid sequence of the coding protein of the cation-Cl-co-transporter protein coding gene PcCCC1 is as shown in SEQ ID No.2, and the sequence of a specific promoter of the cation-Cl-co-transporter protein coding gene PcCCC1 is as shown in SEQ ID No.3. The invention further discloses an application of the cation-Cl-co-transporter protein coding gene PcCCC1. Experiments prove that after the gene is driven by a specific promoter of the gene to be overexpressed in arabidopsis thaliana, accumulation of Na < + > and Cl <-> of the overground part under salt stress can be reduced, so that the salt tolerance of the plant is improved, a gene resource is provided for improvement of the salt tolerance of the plant, and the gene has a wide application value.

Provided are a method, system, and computer-readable medium for optimizing glycemic control of a diabetic subject having Type 1 diabetes through co-administration of sodium-glucose cotransporter inhibitors (SGLTi) and insulin. Such co-administration can be effected by, for example, regulating one or more administration reactions in view of analyses of continuous glucose monitoring (CGM) data that can be indicative of at least the potential for one or more glycemic events including hypoglycemia and hyperglycemia. The aforementioned regulation can occur according to a balancing of insulin infusion and provisioning of SGLTi so as to avoid the occurrence of either of such events while, at the same time, not promoting an instance of diabetic ketoacidosis (DKA).

The present invention relates to a method of detecting effects induced by a sodium-glucose cotransporter inhibitor (SGLTi) in a subject suffering from a cardiovascular disease, the method comprising a) determining the amount of fatty acid binding protein 3 (FABP3) in a sample of the subject treated with SGLTi; and b) comparing the amount of FABP3 to a reference amount. Computer-implemented methods, computer program products, devices and kits for performing the methods of the invention are also encompassed. The invention further relates to the use of FABP3, the use of FABP3 and a marker of cardiac injury, and / or the use of a detection agent of FABP3 or the use of a detection agent of FABP3 and a marker of cardiac injury for detecting effects induced by a sodium-glucose cotransporter inhibitor (SGLTi) in a subject suffering from cardiovascular disease.

The invention relates to the technical field of biological medicines, in particular to a novel polypeptide for regulating the activity of a sodium glucose cotransporter 2 (SGLT2), which consists of the following four amino acid sequences: SEQ. NO: 1: Asp-Pro-Gly-Leu-Thr (DPGLT), SEQ. NO: 2: His-Cys-Val-Arg-Asn (HCVRN), SEQ. NO: 3: Gly-Met-Ser-Lys-Phe (GMSKF), and SEQ. NO: 4: Tyr-Trp-Arg-His-Glu (YWRHE). The invention also relates to a preparation method of the novel polypeptide for regulating the activity of the SGLT2. Experimental results show that the novel polypeptide can effectively inhibit the activity of SGLT2, regulate the blood glucose level, improve blood glucose control and reduce the blood glucose level.

Methods of treating type 1 diabetes, improving cardiovascular health, delaying renal function decline, reducing the risk of cardiovascular death and reducing the risk of heart failure hospitalization, while minimizing adverse events such as diabetic ketoacidosis and severe hypoglycemia, using sodium-glucose cotransporter 2 (SGLT2) inhibitors are disclosed. In a preferred method, the SGLT2 inhibitor is sofogliflozin. Also disclosed are prescriptions for developing sofogliflozin and methods of administering sofogliflozin.

The application belongs to the technical field of biological medicine, and particularly relates to a micro binding protein targeting sodium-glucose cotransporter 2 and a construction method and application thereof. The amino acid sequence of the micro binding protein is shown in SEQ ID NO. 5, and the micro binding protein is a triple helix structure. The micro binding protein targeting sodium-glucose cotransporter 2 (sglt2) provided in the application can be combined with the sglt2 protein as a tool protein, is used for regulating cell glucose absorption, and can be used for fluorescence detection of the sglt2 protein through the micro binding protein marked with a specific label. The micro binding protein in the application can be applied to sglt2 function regulation and fluorescence label detection as a novel sglt2 tool.

The present disclosure relates to the endothelin receptor antagonist (ERA) zibotentan in combination with the sodium-dependent glucose cotransporter 2 (SGLT-2) inhibitor dapagliflozin for use in the treatment of certain endothelin related diseases.

The present invention relates to a pharmaceutical composition containing a sodium-glucose cotransporter-2 inhibitor and an angiotensin II receptor blocker for the prevention or treatment of obesity. The pharmaceutical composition has no problem of interaction between drugs, shows a synergistic effect on weight loss, achieves rapid weight loss at the beginning of administration, and exhibits an effect of maintaining weight loss independent of dietary intake during long-term administration, and thus can be effectively applied to obese patients.

This disclosure relates to composition and methods for the treatment, prevention and reduction of a comorbidity associated with chronic inflammation such as obesity, Type 1 Diabetes (T1), Type 2 Diabetes (T2D), metabolic syndrome, chronic kidney disease, and cardiovascular risk, as well as methods for improving the efficacy of GLP-1 agonists.

The invention relates to a sodion-taurocholic acid co-transport protein (NTCP) long-acting inhibitor and application thereof, and provides a sodion-taurocholic acid co-transport protein (NTCP) long-acting inhibitor and application of the sodion-taurocholic acid co-transport protein (NTCP) long-acting inhibitor. In particular, provided are long-acting polypeptides that can be used as NTCP inhibitors. The invention also relates to a preparation method and application of the polypeptide, and a pharmaceutical composition containing the polypeptide. The NTCP long-acting inhibitor competitively inhibits the binding between hepatitis virus surface protein and NTCP through binding with NTCP, realizes the hepatitis virus entry inhibition effect, and can be used as a therapeutic or prophylactic drug for blocking hepatitis virus from entering cells, a hepatitis recurrence inhibition drug and a hepatitis functional curing drug; the compound can also be used as a medicine for treating type II diabetes, a medicine for treating obesity and a medicine for treating intestinal autoimmune diseases, biliary cirrhosis and atherosclerosis.

The invention provides a composition for preventing or treating neurodegenerative diseases and a use method thereof. The composition comprises a phosphodiesterase-5 (PDE-5) inhibitor and an anti-diabetes therapeutic agent comprising a sodium-glucose cotransporter 2 (SGLT2) inhibitor and a dipeptidyl peptidase-4 (PPD-4) inhibitor; wherein the PDE5 inhibitor is selected from the group consisting of mironafil, sildenafil, vardenafil, tadalafil, udenafil, dabigatafil, avanafil, pharmaceutically acceptable salts, solvates, hydrates, and mixtures thereof; and the SGLT2 inhibitor is selected from the group consisting of canagliflozin, dapagliflozin, empagliflozin, ertugliflozin, ipagliflozin, luseogliflozin, tofogliflozin, repagliflozin etabate, sersegliflozin etabate, pharmaceutically acceptable salts, solvates, hydrates, and mixtures thereof; and the neurodegenerative disease is selected from the group consisting of dementia, Parkinson's disease (PD), dementia with Lewy bodies (DLB), Alzheimer's disease (AD), Huntington's disease (HD), multiple sclerosis (MS), vascular dementia (VaD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia or a mixed cause thereof.

Disclosed herein are methods of treating metabolic disorders, wherein the method administers a combination of a sodium / glucose co-transporter 1 (SGLT1) inhibitor and a glucagon-like peptide agonist 1 (GLP 1), a Gastrosuppressive Peptide-1 (GIP-1) analog, and / or d) a dual GLP-1-GIP-1 receptor agonist.

The present disclosure relates to the field of diseases caused by reduced synaptic inhibition, preferably those caused by reduced activity of potassium (K) / chlorine (Cl) cotransporter (KCC2). The present disclosure relates to oligonucleotides and their use in RNA editing methods that target the target adenosine in the SLC12A5 precursor mRNA encoding KCC2 or in the codon encoding the phosphorylation site in the mRNA, preferably the adenosine in the codon encoding threonine at position 1007 of the KCC2b isoform. Through editing, threonine is replaced by alanine, so that phosphorylation sites are removed, and the activity of KCC2 protein in the process of recovering GABA (gamma-aminobutyric acid) capable of inhibiting tension is increased. The disclosure further relates to oligonucleotides for the treatment of chronic pain and epilepsy.

The invention discloses a new application of a sodium-glucose cotransporter 2 inhibitor in preparation of drugs for treatment and / or adjuvant treatment of ascites due to cirrhosis. The sodium-glucose cotransporter 2 inhibitor disclosed by the invention can take effect together with furosemide, effectively increases urine sodium and urine excretion of intractable or intractable ascites due to cirrhosis caused by diuretic resistance, improves the uncomfortable symptoms of abdominal distension of the patients, reduces the total amount of ascites, and is good in treatment effect and free of toxic and side effects. The treatment dilemma that the ascites of the patients cannot be effectively reduced by medicines in the prior art is effectively solved.

Disclosed herein are methods of treating diabetic cardiomyopathy (DbCM) using an aldose reductase inhibitor, and methods of inhibiting decline in cardiac functional capacity and / or progression to overt heart failure in a subject with DbCM using an aldose reductase inhibitor. Also disclosed are aldose reductase inhibitors and compositions thereof for use in treating diabetic cardiomyopathy (DbCM), or inhibiting decline in cardiac functional capacity and / or progression to overt heart failure in a subject with DbCM. Subjects treated by the methods and uses are not administered a sodium-glucose cotransporter-2 (SGLT2) inhibitor and / or have an HbA1C value greater than 8.5%.

This disclosure relates to the use of compounds and pharmaceutical compositions thereof in the preparation of medicaments for the prevention and / or treatment of myopia. The compounds disclosed herein are medicaments for treating diabetes, selected from at least one of glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter 2 inhibitors, insulin sensitizers, or dipeptidyl peptidase-4 inhibitors. This disclosure provides novel compounds for the prevention and / or treatment of myopia, and to further improve efficacy, this disclosure also provides pharmaceutical compositions comprising said compounds.

According to one aspect of the present invention, this method for detecting Fusobacterium nucleatum in a sample involves a step for subjecting a DNA derived from a sample to nucleic acid amplification reaction using a primer set specific to a citrate lyase beta subunit gene of Fusobacterium nucleatum. According to said method, F. nucleatum can be specifically detected. According to another aspect of the present invention, this method for detecting Fusobacterium nucleatum nucleatum in a sample involves a step for subjecting a DNA derived from a sample to nucleic acid amplification reaction using a primer set specific to a dicarboxylate / amino acid: cation cotransporter gene of Fusobacterium nucleatum nucleatum. According to said method, F. nucleatum nucleatum can be specifically detected.

The invention relates to the technical field of biological medicines, in particular to a novel polypeptide for regulating the activity of a sodium glucose cotransporter 2 (SGLT2), which consists of the following four amino acid sequences: SEQ. NO: 1: Asp-Pro-Gly-Leu-Thr (DPGLT), SEQ. NO: 2: His-Cys-Val-Arg-Asn (HCVRN), SEQ. NO: 3: Gly-Met-Ser-Lys-Phe (GMSKF), and SEQ. NO: 4: Tyr-Trp-Arg-His-Glu (YWRHE). The invention also relates to a preparation method of the novel polypeptide for regulating the activity of the SGLT2. Experimental results show that the novel polypeptide can effectively inhibit the activity of SGLT2, regulate the blood glucose level, improve blood glucose control and reduce the blood glucose level.

This disclosure relates to composition and methods for the treatment, prevention and reduction of a comorbidity associated with chronic inflammation such as obesity, Type 1 Diabetes (T1), Type 2 Diabetes (T2D), metabolic syndrome, chronic kidney disease, and cardiovascular risk, as well as methods for improving the efficacy of GLP-1 agonists.

Combination treatment with SGLT2 inhibitor plus the epigenetic inhibitor tazemetostat significantly improves the response of lung cancer to SGLT2 inhibitors in a genetically engineered murine model. Likewise, combination treatment with SGLT2 inhibitor and a nutritional supplement, dimethyl-alpha-ketoglutarate, also potentiates SGLT2 treatment, as it acts on the same pathway targeted by tazemetostat. This provides a method of inhibiting the development or progression of a pre-malignant lesion in a subject by administering to the subject: (a) an effective amount of an inhibitor of sodium / glucose cotransporter (SGLT); and (b) an effective amount of an α-ketoglutarate, and / or of an inhibitor of enhancer of zeste homolog 2 (EZH2). The lesion is typically a lung lesion, such as atypical adenomatous hyperplasia (AAH), adenocarcinoma in situ, invasive adenocarcinoma, and / or minimally invasive adenocarcinoma.

A compound inhibiting a sodium-glucose cotransporter 1, and a pharmaceutically acceptable salt and a stereoisomer thereof. The compound is used in a pharmaceutical composition. Also disclosed are methods for preparing and using the pharmaceutical composition, and an application in preparing a drug and a composition of the compound for treating and improving diabetes cardio-vascular diseases, weight reduction, fatty liver, astriction, and metabolism-related diseases, and cancer therapy.

The invention relates to an oral pharmaceutical preparation containing a sodium-glucose cotransporter 2 inhibitor and an angiotensin II receptor blocker, and the sodium-glucose cotransporter 2 inhibitor and the angiotensin II receptor blocker which are independently taken before can be prepared into an oral single compound preparation. The present invention relates to a pharmaceutical composition, which can be implemented in a relatively small size, thereby improving ease of administration and patient compliance, and can be effectively used in patients requiring long-term administration, such as type 2 diabetes, hypertension, hypertension associated with diabetes, heart failure, and the like, since there is no drug interaction problem.

This disclosure relates to the field of diseases caused by reduced synaptic inhibition, preferably diseases caused by reduced activity of the potassium (K) / chloride (Cl) cotransporter (KCC2). This disclosure relates to oligonucleotides in RNA editing methods and their use in targeting adenosine in a codon encoding a phosphorylation site in the SLC12A5 mRNA precursor or mRNA encoding KCC2, preferably adenosine in a codon encoding threonine at position 1007 of the KCC2b isoform. Through editing, threonine is replaced by alanine, thereby removing the phosphorylation site and thereby increasing the activity of the KCC2 protein in a process that restores its GABAergic inhibitory tendency. This disclosure further relates to oligonucleotides for use in the treatment of chronic pain and epilepsy.

The present invention provides nanoparticles or conjugates comprising at least one ligand that selectively targets sodium-myoinositol cotransporter-1 (SMIT1) or H+- myoinositol transporter (HMIT). In various embodiments, the nanoparticles or conjugates of the invention target at least one cell comprising HMIT, SMIT, and / or SMIT1 (e.g., endothelial cells of blood brain barrier). In some embodiments, the nanoparticles or conjugates of the invention cross the blood brain barrier. In other aspects, the present invention relates to methods for in vivo delivery of diagnostic and / or therapeutic agents to a brain. In other aspects, the present invention relates to methods of preventing or treating a neurological or cognitive disease or disorder using the nanoparticles or conjugates of the invention.

The present invention provides a composition for preventing or treating a neurodegenerative disease containing a phosphodiesterase-5 (PDE-5) inhibitor and an anti-diabetic therapeutic including sodium-glucose cotransporter 2 (SGLT2) inhibitor and a dipeptidyl peptidase-4 (PPD-4) inhibitor and a method using thereof, wherein the PDE5 inhibitor is selected from among mirodenafil, sildenafil, vardenafil, tadalafil, udenafil, dasantafil, avanafil, pharmaceutically acceptable salts, solvates, hydrates, and a mixture thereof; and the SGLT2 inhibitor is selected from among canagliflozin, dapagliflozin, empagliflozin, ertugliflozin, ipragliflozin, luseogliflozin, tofogliflozin, remogliflozin etabonate, sergliflozin etabonate, pharmaceutically acceptable salts, solvates, hydrates and a mixture thereof; and the neurodegenerative disease is selected from the group among dementia, Parkinson's disease (PD), Dementia with Lewy body (DLB), Alzheimer's disease (AD), Huntington's disease (HD), Multiple sclerosis (MS), Vascular Dementia (VaD), Amyotrophic Lateral Sclerosis (ALS), frontotemporal dementia, or a mixed etiologies thereof.

The present application relates to a kind of dsRNA of prawn SGLT1 gene and its application.The target sequence of the dsRNA is derived from the coding sequence corresponding to the transmembrane region outside loop, intracellular loop or extracellular loop of sodium-dependent glucose cotransporter SGLT1 gene coding protein.The dsRNA of prawn SGLT1 gene provides a new molecular means for preventing and controlling acute hepatopancreas necrosis disease.The dsRNA molecule can be synthesized by in vitro transcription or prokaryotic / eukaryotic expression system, and can be further constructed to contain the sequence expression cassette, recombinant vector and recombinant bacteria.The dsRNA molecule of the present application is small in molecular weight, biodegradable, and will not cause environmental pollution or drug residue, with the advantages of safety, environmental protection, high efficiency and scale production, etc., and can be used as a new biological agent or feed additive for preventing and controlling Vibrio parahaemolyticus AHPND infection.

Techniques are disclosed for patient population flow modeling in which such modeling may provide insights to future trends in a patient population, e.g., to facilitate allocation of resources to a patient population or notification of treatment suggestions to a patient. A flow model may be used on a dialysis patient population in which patients are grouped into compartments according to a certain criterion (or a given criterion), in which each compartment corresponds to the number of patients in each group, and in which the number of compartments may vary according to the given criterion. Models may then be used to describe slew rates between different compartments, as well as inflow and outflow flows in each compartment. Such models may be used, for example, to study the effect of sodium-glucose cotransporter 2 (SGLT2) inhibitors on the population dynamics of end-stage nephropathy patients.